FDA tomato recall elevated to highest level due to salmonella risk
An ongoing recall of tomatoes in the US has been upgraded to the highest risk level with a 'reasonable probability' of death.
Tomatoes from Williams Farms Repack LLC on Wednesday were designated as a Class I recall by the US Food and Drug Administration (FDA), which is responsible for protecting public health.
The company first recalled its tomatoes on April 30 over fears that they contain salmonella.
A month later, the FDA has labeled it a Class I recall, which poses the greatest health hazard on its scale and is relatively rare.
The FDA defines a Class I recall as 'a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death'.
Affected tomatoes were shipped to three US states – Georgia, North Carolina and South Carolina.
There were 50 three-pack trays of the item distributed, as well as 77 10-pound boxes, and 419 60-count two-layer boxes.
They contain the lot numbers R4467 and R4470, and had the Williams Farms Repack label or an H&C Farms label.
The company based in Lodge, South Carolina, stated at the time that it issued the voluntarily recall that there were no related illness reported.
Salmonella is 'an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems', according to the FDA's original announcement on the recall. More Trending
Healthy people infected with it can experience symptoms including diarrhoea with or without blood, abdominal pain, vomiting, nausea and fever.
More serious salmonella cases are rare, but involve the organism entering the bloodstream and causing arthritis, endocarditis and arterial infections such as infected aneurysms.
Customers should not consume the tomatoes and return them for a full refund, or throw them away.
A version of this article was previously published on May 30, 2025
Get in touch with our news team by emailing us at webnews@metro.co.uk.
For more stories like this, check our news page.
MORE: Toddler found riding baggage conveyor belt after vanishing from parents at Newark Airport
MORE: US suggests Palestinian state should be in the French Riviera
MORE: Map shows where northern lights will be visible tonight in the US
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
The Independent
2 hours ago
- The Independent
Alzheimer's blood test ‘can accurately pick up early symptoms'
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
Reuters
20 hours ago
- Reuters
Four Democratic-led US states urge FDA to remove abortion pill restrictions
NEW YORK, June 5 (Reuters) - The attorneys general of New York, California, Massachusetts and New Jersey asked the Food and Drug Administration to expand access to the abortion pill mifepristone, and remove what they view as outdated and medically unnecessary restrictions. Thursday's petition by the Democratic-led states seeks to force the FDA to acknowledge what the states view as "extensive" evidence that mifepristone is safe, notwithstanding the Trump administration's general opposition to abortion. It came after Health and Human Services Secretary Robert F. Kennedy Jr told Congress last month he ordered FDA Commissioner Marty Makary to review the pill, and unspecified "alarming" new data suggested the government should at least change the label. Mifepristone is the first pill, followed by the drug misoprostol, for medication abortion in the first 10 weeks of pregnancy, and won FDA approval in 2000. Medication abortions account for more than half of U.S. abortions, though 28 states restrict access, according to the nonprofit Guttmacher Institute, which focuses on reproductive health. The petition challenges FDA requirements that mifepristone prescribers be included in national and local abortion provider lists, patients attest in writing that they intend to end their pregnancies, and pharmacies perform a variety of recordkeeping. Citing the drug's safety record, it said those rules, part of the FDA's Risk Evaluation and Mitigation Strategy program, are "no longer justified by science or law," especially in states where abortion is legal and comprehensively regulated. New York Attorney General Letitia James said the rules keep mifepristone out of reach of most primary care settings. She called that problem particularly acute in rural and other areas where getting abortions often requires lengthy travel. "There is simply no scientific or medical reason to subject it to such extraordinary restrictions," James said, referring to mifepristone. "The FDA must follow the science." A spokeswoman for the Department of Health and Human Services said FDA Commissioner Makary "will ensure gold standard science is used while incorporating practical, common-sense considerations to its regulatory processes." Many states, primarily Republican-led or leaning, have restricted or substantially eliminated abortions in the three years since the U.S. Supreme Court overturned Roe v. Wade, the 1973 decision that legalized the procedure nationwide. Last June, the Supreme Court preserved broad access to mifepristone, unanimously ruling that a group of anti-abortion organizations and doctors lacked legal standing to challenge the FDA's approval of the pill. Despite largely siding with abortion opponents, Republican President Donald Trump said during his 2024 campaign he did not plan to limit access to mifepristone. Last month, the administration asked a federal judge to dismiss, on procedural grounds, a lawsuit by three generally Republican states seeking to narrow such access. That lawsuit began during the administration of Democratic President Joe Biden, who generally supported abortion access. Seventeen other Democratic-led or -leaning states plus Washington, D.C., are separately suing the FDA in Spokane, Washington, to loosen restrictions on mifepristone. They said doctors and pharmacies should be able to dispense the pill, as with most drugs, without special certifications. On May 30, the Trump administration urged a dismissal, saying the states didn't show the FDA's policy was flawed or the agency ignored important evidence. The states filed Thursday's petition after a short delay, with the filing having been expected earlier in the morning.
